These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 14562142)

  • 81. A new suicide.
    Bhalerao S
    J Fam Pract; 2001 Jun; 50(6):551. PubMed ID: 11401748
    [No Abstract]   [Full Text] [Related]  

  • 82. Tadalafil-associated priapism.
    King SH; Hallock M; Strote J; Wessells H
    Urology; 2005 Aug; 66(2):432. PubMed ID: 16051318
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Rates of non-arteritic ischemic optic neuropathy in male veterans prescribed phosphodiesterase-5 inhibitors.
    Tsertsvadze A
    Am J Ophthalmol; 2009 Oct; 148(4):625; author reply 625-6. PubMed ID: 19782802
    [No Abstract]   [Full Text] [Related]  

  • 84. [Update of PDE5 inhibitors as treatment of ED].
    Lu YN; Chen B
    Zhonghua Nan Ke Xue; 2005 Jul; 11(7):552-5. PubMed ID: 16078679
    [TBL] [Abstract][Full Text] [Related]  

  • 85. [Topical therapy in erectile dysfunction].
    Floth A
    Wien Med Wochenschr; 2000; 150(1-2):14-7. PubMed ID: 10746290
    [TBL] [Abstract][Full Text] [Related]  

  • 86. [Viagra -- patients stand by their treatment].
    Praxis (Bern 1994); 2006 Nov; 95(47):1835-6. PubMed ID: 17168079
    [No Abstract]   [Full Text] [Related]  

  • 87. Acute angle-closure glaucoma following sildenafil citrate-aided sexual intercourse.
    Ramasamy B; Rowe F; Nayak H; Peckar C; Noonan C
    Acta Ophthalmol Scand; 2007 Mar; 85(2):229-30. PubMed ID: 17305747
    [No Abstract]   [Full Text] [Related]  

  • 88. Risks of self-injection therapy for impotence.
    Millard RJ; Stricker PD; Lynch WJ; Dean TE; Murnaghan GF; Breslin FH
    Med J Aust; 1996 Jul; 165(2):117-8. PubMed ID: 8692055
    [No Abstract]   [Full Text] [Related]  

  • 89. [Treatment of erectile dysfunction with PDE-5 inhibitors. Difficult for the physician to choose between the preparations--the patient should be given the opportunity to try out all three].
    Ströberg P; Hedelin H; Ljunggren C
    Lakartidningen; 2006 Apr 5-11; 103(14):1107-8, 1110-1. PubMed ID: 16681094
    [No Abstract]   [Full Text] [Related]  

  • 90. [Intracavernous injection of vasoactive agents].
    Kawanishi Y
    Nihon Rinsho; 2002 Jun; 60 Suppl 6():285-9. PubMed ID: 12166159
    [No Abstract]   [Full Text] [Related]  

  • 91. [Methylene blue: an effective therapeutic alternative for priapism induced by intracavernous injection of vasoactive agents].
    Martínez Portillo FJ; Fernández Arancibia MI; Bach S; Alken P; Jünemann KP
    Arch Esp Urol; 2002 Apr; 55(3):303-8. PubMed ID: 12068762
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Intraurethral alprostadil for impotence.
    Med Lett Drugs Ther; 1997 Mar; 39(997):32. PubMed ID: 9121395
    [No Abstract]   [Full Text] [Related]  

  • 93. [Priapism of low flow].
    Ruiz Cerda JL; Moreno Pardo B; Server Pastor G; Osca García JM; Vera Donoso C; Jiménez Cruz JF
    Actas Urol Esp; 1991; 15(6):510-4. PubMed ID: 1792989
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Factors associated with preference for sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy: post hoc analysis of data from a multicentre, randomized, open-label, crossover study.
    Eardley I; Montorsi F; Jackson G; Mirone V; Chan ML; Loughney K; Vail GM; Beardsworth A
    BJU Int; 2007 Jul; 100(1):122-9. PubMed ID: 17552960
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Intracavernous self-injection of papaverine and verapamil: a clinical experience.
    Bolayir K; Gökşin N
    Acta Chir Hung; 1994; 34(3-4):253-6. PubMed ID: 7618376
    [TBL] [Abstract][Full Text] [Related]  

  • 96. [Progress in therapy of erectile dysfunction. New orally administered drugs].
    Lenk S
    Internist (Berl); 2002 May; 43(5):670-4. PubMed ID: 12085538
    [No Abstract]   [Full Text] [Related]  

  • 97. Response to Tomsak, R. PDE5 inhibitors and permanent visual loss (Int J Impot Res 2005; 17: 547-549).
    Watt SJ; Primatesta P; Siegel R
    Int J Impot Res; 2006; 18(4):411; author reply 412. PubMed ID: 16819534
    [No Abstract]   [Full Text] [Related]  

  • 98. Risk factors for an early increase in dose of vasoactive agents for intracavernous pharmacotherapy.
    Kim SC; Seo KK; Park BD; Lee SW
    Urol Int; 2000; 65(4):204-7. PubMed ID: 11112870
    [TBL] [Abstract][Full Text] [Related]  

  • 99. [Conservative treatment of erectile dysfunction].
    Papp G; Erdei E
    Orv Hetil; 2003 Jun; 144(22):1061-6. PubMed ID: 12847815
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Effect of phosphodiesterase-5 inhibitor on hearing.
    Okuyucu S; Guven OE; Akoglu E; Uçar E; Dagli S
    J Laryngol Otol; 2009 Jul; 123(7):718-22. PubMed ID: 19134242
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.